Bruce Cozadd to Retire as Chief Executive Officer of Jazz Pharmaceuticals plc Upon Appointment of Successor by the End of 2025 - Marketscreener.com
J7Z Stock | EUR 116.85 1.15 0.97% |
Roughly 61% of Jazz Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Jazz Pharmaceuticals plc suggests that many traders are alarmed regarding Jazz Pharmaceuticals' prospects. The current market sentiment, together with Jazz Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Jazz Pharmaceuticals plc stock news signals to limit their universe of possible portfolio assets.
Jazz Pharmaceuticals stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Jazz daily returns and investor perception about the current price of Jazz Pharmaceuticals plc as well as its diversification or hedging effects on your existing portfolios.
Jazz |
Bruce Cozadd to Retire as Chief Executive Officer of Jazz Pharmaceuticals plc Upon Appointment of Successor by the End of 2025 Marketscreener.com
Read at news.google.com
Jazz Pharmaceuticals Fundamental Analysis
We analyze Jazz Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jazz Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jazz Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earnings To Growth
Price To Earnings To Growth Comparative Analysis
Jazz Pharmaceuticals is currently under evaluation in price to earnings to growth category among its peers. PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Jazz Pharmaceuticals plc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Jazz Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Jazz Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Jazz Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Jazz Pharmaceuticals Related Equities
0QF | Moderna | 4.41 | ||||
1FW1 | WUXI BIOLOGICS | 1.95 | ||||
CSJ | CSL | 0.60 | ||||
MBG | Mercedes Benz | 0.30 | ||||
22UA | BioNTech | 0.46 | ||||
CSJA | CSL | 0.61 | ||||
VX1 | Vertex Pharmaceuticals | 2.47 | ||||
NOVA | Novo Nordisk | 19.28 |
Complementary Tools for Jazz Stock analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |